TRANSLATIONAL GENOMICS RESEARCH INSTITUTE: Form 990, tax year 2015

View the entire original 990 at ProPublica ↗

Organization: TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (EIN 75-3065445)
Tax period: 2015-01-01 to 2015-12-31
Filed: 2016-11-14
IRS object ID: 201623199349307247
Schema version: 2015v2.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule J
Schedule L
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2016-11-14T14:32:27-06:00	ReturnTs
Tax Period End	2015-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	TWO NORTH CENTRAL AVENUE STE 2300	AddressLine1Txt
City	PHOENIX	CityNm
State Abbreviation	AZ	StateAbbreviationCd
ZIP	85004	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2015-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	753065445	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
In Care Of	% KEVIN GROFF	InCareOfNm
Business Name Control	TRAN	BusinessNameControlTxt
Phone	6023438400	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	445 N 5TH STREET Suite 600	AddressLine1Txt
City	PHOENIX	CityNm
State Abbreviation	AZ	StateAbbreviationCd
ZIP	85004	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	Teresa Burleson	PersonNm
Person Title	COO	PersonTitleTxt
Phone	6023438478	PhoneNum
Signature	2016-11-14	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	BRENDA GRIESEMER	PreparerPersonNm
PTIN	P00264669	PTIN
Phone	6023223000	PhoneNum

Field	Value	IRS element (for citing)
Tax	2015	TaxYr
Build TS	2017-02-10 21:41:12Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	JEFFREY M TRENT PHD	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	445 N 5TH STREET600	AddressLine1Txt
City	Phoenix	CityNm
State Abbreviation	AZ	StateAbbreviationCd
ZIP	85004	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$40,945,133	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.TGEN.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	2002	FormationYr
Legal Domicile State	AZ	LegalDomicileStateCd
Activity Or Mission	SEE SCHEDULE O	ActivityOrMissionDesc
Voting Members Governing Body	10	VotingMembersGoverningBodyCnt
Voting Members Independent	9	VotingMembersIndependentCnt
Total Employee	345	TotalEmployeeCnt
Total Volunteers	70	TotalVolunteersCnt
Total Gross UBI	$792,877	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$15,937,701	PYContributionsGrantsAmt
CY Contributions Grants	$21,230,401	CYContributionsGrantsAmt
PY Program Service Revenue	$17,307,268	PYProgramServiceRevenueAmt
CY Program Service Revenue	$16,538,667	CYProgramServiceRevenueAmt
PY Investment Income	$49,382,196	PYInvestmentIncomeAmt
CY Investment Income	$172,192	CYInvestmentIncomeAmt
PY Other Revenue	$1,618,401	PYOtherRevenueAmt
CY Other Revenue	$2,308,719	CYOtherRevenueAmt
PY Total Revenue	$84,245,566	PYTotalRevenueAmt
CY Total Revenue	$40,249,979	CYTotalRevenueAmt
PY Grants And Similar Paid	$0	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$0	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$25,596,001	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$22,715,867	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$0	CYTotalFundraisingExpenseAmt
PY Other Expenses	$30,799,882	PYOtherExpensesAmt
CY Other Expenses	$27,602,138	CYOtherExpensesAmt
PY Total Expenses	$56,395,883	PYTotalExpensesAmt
CY Total Expenses	$50,318,005	CYTotalExpensesAmt
PY Revenues Less Expenses	$27,849,683	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$10,068,026	CYRevenuesLessExpensesAmt
Total Assets BOY	$78,134,333	TotalAssetsBOYAmt
Total Assets EOY	$42,113,953	TotalAssetsEOYAmt
Total Liabilities BOY	$19,850,175	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$18,084,710	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$58,284,158	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$24,029,243	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SEE SCHEDULE O	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$9,786,680	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$569,627	RevenueAmt
Desc	GENOTYPING TECHNOLOGY CENTER - SEE SCHEDULE O	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$8,629,700	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$1,004,079	RevenueAmt
Desc	NEUROGENOMICS DIVISION - SEE SCHEDULE O	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$8,150,188	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$3,384,640	RevenueAmt
Desc	INTEGRATED CANCER GENOMICS DIVISION - SEE SCHEDULE O	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$3,711,313	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$0	TotalOtherProgSrvcGrantAmt
Total Other Prog Srvc Revenue	$13,096,163	TotalOtherProgSrvcRevenueAmt
Total Program Service Expenses	$30,277,881	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Temp Or Permanent Endowments	Yes (true)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	Yes (true)	ReportOtherAssetsInd
Report Other Liabilities	Yes (true)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	false	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	false	ProfessionalFundraisingInd
Fundraising Activities	false	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	false	GrantsToOrganizationsInd
Grants To Individuals	false	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	Yes (true)	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	Yes (true)	DisregardedEntityInd
Related Entity	Yes (true)	RelatedEntityInd
Related Organization Ctrl Ent	Yes (true)	RelatedOrganizationCtrlEntInd
Transaction With Control Ent	Yes (true)	TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	32	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	345	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	false	QuidProQuoContributionsInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	10	GoverningBodyVotingMembersCnt
Independent Voting Member	9	IndependentVotingMemberCnt
Family Or Business Rln	Yes (true)	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	false	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	Yes (true)	InvestmentInJointVentureInd
Written Policy Or Procedure	Yes (true)	WrittenPolicyOrProcedureInd
States Where Copy Of Return Is Fld	AZ	StatesWhereCopyOfReturnIsFldCd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	KEVIN GROFF	PersonNm
Phone	6023438478	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	445 N 5th Street Suite 600	AddressLine1Txt
City	PHOENIX	CityNm
State Abbreviation	AZ	StateAbbreviationCd
ZIP	85004	ZIPCd

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	Yes (X)	InfoInScheduleOPartVIIInd

Form990 Part VII Section A Form990PartVIISectionAGrp (24 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd
Jeffrey M Trent PhD
BOARD MEMBER/PRES/SCIENCE DIR.	39.0	1.0	Yes (X)	Yes (X)	$999,967	$0	$220,796
William J Post
Board Member/Chairman	1.0	1.0	Yes (X)	Yes (X)	$0	$0	$0
Cindy Parseghian
Board Member/Treasurer	1.0	0.0	Yes (X)	Yes (X)	$0	$0	$0
Bennett Dorrance
Board Member /Secretary	1.0	1.0	Yes (X)	Yes (X)	$0	$0	$0
Richard L Boals
Board Member	1.0	0.0	Yes (X)		$0	$0	$0
Governor Jan Brewer
Board Member (THRU 1/9/15)	1.0	0.0	Yes (X)		$0	$0	$0
Robert Bulla
Board Member	1.0	0.0	Yes (X)		$0	$0	$0
Bert A Getz
Board Member (THRU 10/13/15)	1.0	0.0	Yes (X)		$0	$0	$0
David J Gullen MD
Board Member	1.0	0.0	Yes (X)		$0	$0	$0
Jeffrey Moorad
Board Member	1.0	0.0	Yes (X)		$0	$0	$0
Richard Silverman
Board Member	1.0	0.0	Yes (X)		$0	$0	$0
The Honorable Greg Stanton
Board Member	1.0	0.0	Yes (X)		$0	$0	$0
Teresa Burleson
CHIEF OPERATING OFFICER	39.0	1.0		Yes (X)	$547,980	$0	$55,384
Michael Berens
Deputy Director of Research	40.0	0.0			$345,423	$0	$19,851	Yes (X)
John Carpten
Deputy Director of Sciences	40.0	0.0			$680,856	$0	$21,100	Yes (X)
David Craig
Deputy Director of Informatics	40.0	0.0			$574,701	$0	$20,531	Yes (X)
James Lowey
Vice President, Technology	40.0	0.0			$199,488	$0	$9,475	Yes (X)
Daniel Von Hoff
Executive Vice President	40.0	0.0			$817,646	$0	$17,297	Yes (X)
Patrick Smith
VP, Corporate Development	40.0	0.0			$641,343	$0	$244,600		Yes (X)
Manuel Estrada
Vice President, Finance	40.0	0.0			$232,636	$0	$16,367		Yes (X)
David Duggan
Associate Professor	40.0	0.0			$225,575	$0	$22,475		Yes (X)
Michael Bittner
Professor	40.0	0.0			$225,431	$0	$16,465		Yes (X)
James Harris
VP, Business Development	40.0	0.0			$218,448	$0	$11,161		Yes (X)
CHARLES K COLESON
CHIEF FINANCIAL OFFICER	29.0	1.0			$157,822	$0	$1,974			Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$5,867,316	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$677,476	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	51	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	Yes (true)	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (3 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
FirstStrategic
300 W Clarendon Ave Suite 460	Phoenix	AZ	85013	Consulting Services	$216,000
Cancer Research and Biostatistics
1730 Minor Ave Suite 1900	Seattle	WA	98101	Research Services	$203,839
Tech66 LLC
4557 E Via Los Caballos	Phoenix	AZ	85028	Consulting Services	$115,950

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	3	CntrctRcvdGreaterThan100KCnt
Fundraising	$0	FundraisingAmt
Related Organizations	$6,881,065	RelatedOrganizationsAmt
Government Grants	$7,398,685	GovernmentGrantsAmt
All Other Contributions	$6,950,651	AllOtherContributionsAmt
Noncash Contributions	$304,546	NoncashContributionsAmt
Total Contributions	$21,230,401	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	Research Contracts	Desc
Business	541711	BusinessCd
Total Revenue Column	$16,538,667	TotalRevenueColumnAmt
Related Or Exempt Func Income	$16,538,667	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$16,538,667	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$138,143	TotalRevenueColumnAmt
Exclusion	$138,143	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Other	$729,203	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Other	$695,154	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Other	$34,049	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$34,049	TotalRevenueColumnAmt
Exclusion	$34,049	ExclusionAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
JOINT VENTURE SHARED SERVICES	900099	$396,073	$0	$396,073	$0
K-1 PARTNERSHIP REVENUE	900099	$396,804	$0	$396,804	$0
ALL OTHER REVENUE	900099	$1,515,842	$1,515,842	$0	$0

Field	Value	IRS element (for citing)
Other Revenue Total	$2,308,719	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$40,249,979	TotalRevenueColumnAmt
Related Or Exempt Func Income	$18,054,509	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$792,877	UnrelatedBusinessRevenueAmt
Exclusion	$172,192	ExclusionAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part IX	Yes (X)	InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$4,780,495	TotalAmt
Program Services	$1,816,588	ProgramServicesAmt
Management And General	$2,963,907	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$159,796	TotalAmt
Management And General	$159,796	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$14,535,740	TotalAmt
Program Services	$7,415,522	ProgramServicesAmt
Management And General	$7,120,218	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$545,411	TotalAmt
Program Services	$261,797	ProgramServicesAmt
Management And General	$283,614	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,426,938	TotalAmt
Program Services	$684,930	ProgramServicesAmt
Management And General	$742,008	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$1,267,487	TotalAmt
Program Services	$608,394	ProgramServicesAmt
Management And General	$659,093	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$280,062	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$280,062	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$371,861	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$371,861	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$129,600	TotalAmt
Program Services	$129,600	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Fundraising	$0	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$6,966,053	TotalAmt
Program Services	$5,572,843	ProgramServicesAmt
Management And General	$1,393,210	ManagementAndGeneralAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$51,523	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$51,523	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$7,674,629	TotalAmt
Program Services	$5,755,971	ProgramServicesAmt
Management And General	$1,918,658	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$1,739,383	TotalAmt
Program Services	$869,692	ProgramServicesAmt
Management And General	$869,691	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$5,932,661	TotalAmt
Program Services	$4,449,496	ProgramServicesAmt
Management And General	$1,483,165	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$391,263	TotalAmt
Program Services	$156,505	ProgramServicesAmt
Management And General	$234,758	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$315,461	TotalAmt
Program Services	$126,184	ProgramServicesAmt
Management And General	$189,277	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$9,000	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$9,000	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$2,963,029	TotalAmt
Program Services	$2,222,272	ProgramServicesAmt
Management And General	$740,757	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$342,938	TotalAmt
Program Services	$34,294	ProgramServicesAmt
Management And General	$308,644	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
DUES & SUBSCRIPTIONS	$81,291	$32,517	$48,774	$0
SEMINARS & TRAINING	$64,031	$25,536	$38,495	$0
RECRUITMENT	$59,253	$23,701	$35,552	$0
RELOCATION	$29,319	$11,727	$17,592	$0

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$200,781	TotalAmt
Program Services	$80,312	ProgramServicesAmt
Management And General	$120,469	ManagementAndGeneralAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$50,318,005	TotalAmt
Program Services	$30,277,881	ProgramServicesAmt
Management And General	$20,040,124	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$24,631,525	BOYAmt
EOY	$14,016,750	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$7,600,747	BOYAmt
EOY	$6,132,307	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$3,525,069	BOYAmt
EOY	$2,728,066	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$1,037,099	BOYAmt
EOY	$1,197,948	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$2,029,667	BOYAmt
EOY	$1,913,864	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$30,182,697	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$23,388,501	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$8,228,671	BOYAmt
EOY	$6,794,196	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$24,849,594	BOYAmt
EOY	$1,753,446	EOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$6,231,961	BOYAmt
EOY	$7,577,376	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$78,134,333	BOYAmt
EOY	$42,113,953	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$5,949,564	BOYAmt
EOY	$2,486,497	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$10,380,601	BOYAmt
EOY	$11,119,454	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$1,767,395	BOYAmt
EOY	$3,453,462	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$1,752,615	BOYAmt
EOY	$1,025,297	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$19,850,175	BOYAmt
EOY	$18,084,710	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$49,744,801	BOYAmt
EOY	$16,211,722	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$8,539,357	BOYAmt
EOY	$7,817,521	EOYAmt

Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$58,284,158	BOYAmt
EOY	$24,029,243	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$78,134,333	BOYAmt
EOY	$42,113,953	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	-$10,068,026	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$23,572,018	NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts	$0	DonatedServicesAndUseFcltsAmt
Investment Expense	$0	InvestmentExpenseAmt
Prior Period Adjustments	-$218,067	PriorPeriodAdjustmentsAmt
Other Changes In Net Assets	-$396,804	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	Yes (true)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (true)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$27,781,232	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,315,103	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$25,261,567	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$15,937,701	CurrentTaxYearMinus1YearAmt
Current Tax Year	$21,230,401	CurrentTaxYearAmt
Total	$92,526,004	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus1 Year	$0	CurrentTaxYearMinus1YearAmt
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus1 Year	$0	CurrentTaxYearMinus1YearAmt
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$27,781,232	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,315,103	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$25,261,567	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$15,937,701	CurrentTaxYearMinus1YearAmt
Current Tax Year	$21,230,401	CurrentTaxYearAmt
Total	$92,526,004	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$25,313,359	SubstantialContributorsTotAmt
Public Support Total170	$67,212,645	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$20,014	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,668	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$175,334	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$154,921	CurrentTaxYearMinus1YearAmt
Current Tax Year	$138,143	CurrentTaxYearAmt
Total	$490,080	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$93,016,084	TotalSupportAmt
Gross Receipts Rltd Activities	$83,902,909	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.72259	PublicSupportCY170Pct
Public Support PY170	0.78975	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE A, PART II, COLUMN (B)	FormAndLineReferenceDesc
Explanation	THE AMOUNTS INCLUDED IN PART II, COLUMN(B) ARE FOR A SHORT PERIOD, 12/01/2012 - 12/31/2012.	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Total Grassroots Lobbying		TotalGrassrootsLobbyingGrp
Total Direct Lobbying		TotalDirectLobbyingGrp
Total Lobbying Expend		TotalLobbyingExpendGrp
Other Exempt Purpose Expend		OtherExemptPurposeExpendGrp
Total Exempt Purpose Expend		TotalExemptPurposeExpendGrp
Lobbying Nontaxable Amount		LobbyingNontaxableAmountGrp
Grassroots Nontaxable		GrassrootsNontaxableGrp
Tot Lbbyng Grassroot Mns Non Tx		TotLbbyngGrassrootMnsNonTxGrp
Tot Lbby Expend Mns Lbbyng Non Tx		TotLbbyExpendMnsLbbyngNonTxGrp
Volunteers	false	VolunteersInd
Paid Staff Or Management	false	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Media Advertisements	$0	MediaAdvertisementsAmt
Mailings Members	false	MailingsMembersInd
Mailings Members	$0	MailingsMembersAmt
Publications Or Broadcast	false	PublicationsOrBroadcastInd
Publications Or Broadcast	$0	PublicationsOrBroadcastAmt
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Grants Other Organizations	$0	GrantsOtherOrganizationsAmt
Direct Contact Legislators	false	DirectContactLegislatorsInd
Direct Contact Legislators	$0	DirectContactLegislatorsAmt
Rallies Demonstrations	false	RalliesDemonstrationsInd
Rallies Demonstrations	$0	RalliesDemonstrationsAmt
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$129,600	OtherActivitiesAmt
Total Lobbying Expenditures	$129,600	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART II-B, LINE 1I	FormAndLineReferenceDesc
Explanation	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USES A THIRD PARTY COMMUNICATIONS AND PUBLIC AFFAIRS FIRM TO COORDINATE LOBBYING EFFORTS ON BEHALF OF TGEN THROUGH COMMUNICATIONS TO LOCAL GOVERNMENT, LEGISLATIVE AND FEDERAL OFFICIALS AND COMMUNITY LEADERS ON TGEN ACTIVITIES.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amounts		ArtPublicExhibitionAmountsGrp
Held Works Art		HeldWorksArtGrp

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,063,382	BeginningYearBalanceAmt
Investment Earnings Or Losses	-$210,006	InvestmentEarningsOrLossesAmt
Other Expenditures	$530,486	OtherExpendituresAmt
End Year Balance	$5,322,890	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,491,947	BeginningYearBalanceAmt
Investment Earnings Or Losses	$94,127	InvestmentEarningsOrLossesAmt
Other Expenditures	$522,692	OtherExpendituresAmt
End Year Balance	$6,063,382	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,571,997	BeginningYearBalanceAmt
Investment Earnings Or Losses	$456,554	InvestmentEarningsOrLossesAmt
Other Expenditures	$536,604	OtherExpendituresAmt
End Year Balance	$6,491,947	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,553,530	BeginningYearBalanceAmt
Investment Earnings Or Losses	$53,629	InvestmentEarningsOrLossesAmt
Other Expenditures	$35,162	OtherExpendituresAmt
End Year Balance	$6,571,997	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,331,923	BeginningYearBalanceAmt
Investment Earnings Or Losses	$643,547	InvestmentEarningsOrLossesAmt
Other Expenditures	$421,940	OtherExpendituresAmt
End Year Balance	$6,553,530	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Term Endowment Balance EOY	1.00000	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Book Value	$0	BookValueAmt

Field	Value	IRS element (for citing)
Buildings		BuildingsGrp

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	$0	InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis	$5,343,943	OtherCostOrOtherBasisAmt
Depreciation	$2,265,804	DepreciationAmt
Book Value	$2,778,139	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	$0	InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis	$22,498,449	OtherCostOrOtherBasisAmt
Depreciation	$18,548,533	DepreciationAmt
Book Value	$3,949,916	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	$0	InvestmentCostOrOtherBasisAmt
Other Cost Or Other Basis	$2,340,305	OtherCostOrOtherBasisAmt
Depreciation	$2,274,164	DepreciationAmt
Book Value	$66,141	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$6,794,196	TotalBookValueLandBuildingsAmt

Other Assets Org OtherAssetsOrgGrp (3 entries)

DescDesc	Book ValueBookValueAmt
DUE FROM TGEN FOUNDATION	$5,532,671
INVESTMENT IN 457(B) PLAN	$1,025,296
IN-KIND DONATED ASSETS	$1,019,409

Field	Value	IRS element (for citing)
Total Book Value Other Assets	$7,577,376	TotalBookValueOtherAssetsAmt
Federal Income Tax Liability	$0	FederalIncomeTaxLiabilityAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

Field	Value	IRS element (for citing)
Desc	DUE TO EMPLOYEE 457(B) PLAN	Desc
Amt	$1,025,297	Amt

Field	Value	IRS element (for citing)
Total Liability	$1,025,297	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE D, PART V, LINE 4	FormAndLineReferenceDesc
Explanation	TGEN'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A SPECIFIC NUMBER OF SUMMER INTERNS EACH YEAR FOR 25 YEARS. THE INSTITUTE CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. SCHEDULE D, PART X, LINE 2 MANAGEMENT IS OF THE OPINION THAT SUBSTANTIALLY ALL OF TGEN'S AND THE FOUNDATION'S ACTIVITIES ARE RELATED TO THEIR EXEMPT PURPOSES, AND NO MATERIAL UNCERTAIN TAX POSITIONS HAVE BEEN IDENTIFIED OR RECORDED IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS AT DECEMBER 31, 2015 OR 2014. TGEN AND THE FOUNDATION FILE FORMS 990 IN THE U.S. FEDERAL JURISDICTION AND COMPARABLE FORMS IN THE STATE OF ARIZONA. TAX FILINGS FOR 2012 THROUGH 2015 ARE SUBJECT TO EXAMINATION; HOWEVER, THE INSTITUTE HAS NOT BEEN NOTIFIED OF ANY SUCH EXAMINATIONS.	ExplanationTxt

Schedule F IRS990ScheduleF

Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
East Asia and the Pacific	Program services	RESEARCH SERVICES	$59,077
East Asia and the Pacific	Program services	SOFTWARE SERVICES	$3,780
Europe (Including Iceland and Greenland)	Program services	RESEARCH SERVICES	$115,963
North America	Program services	RESEARCH SERVICES	$51,758
North America	Program services	SOFTWARE SERVICES	$10,000
South Asia	Program services	SOFTWARE SERVICES	$194,297

Field	Value	IRS element (for citing)
Subtotal Spent	$434,875	SubtotalSpentAmt
Total Spent	$434,875	TotalSpentAmt
Transfer To Foreign Corp	false	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	false	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE F, PART I, LINE 3, COLUMN (F)	FormAndLineReferenceDesc
Explanation	THE AMOUNTS REPORTED IN COLUMN (F) ARE DETERMINED BASED ON THE ACCRUAL METHOD OF ACCOUNTING.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
First Class Or Charter Travel	Yes (X)	FirstClassOrCharterTravelInd
Written Policy Ref T And E Expnss	Yes (true)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (true)	SubstantiationRequiredInd
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (true)	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Jeffrey M Trent PhD
BOARD MEMBER/PRES/SCIENCE DIR.	$965,834	$0	$0	$0	$34,133	$0	$210,600	$0	$10,196	$0	$1,220,763	$0	$0	$0
Teresa Burleson
CHIEF OPERATING OFFICER	$430,331	$0	$116,667	$0	$982	$0	$48,100	$0	$7,284	$0	$603,364	$0	$100,000	$0
Michael Berens
Deputy Director of Research	$322,496	$0	$0	$0	$22,927	$0	$10,600	$0	$9,251	$0	$365,274	$0	$0	$0
John Carpten
Deputy Director of Sciences	$330,907	$0	$348,967	$0	$982	$0	$10,600	$0	$10,500	$0	$701,956	$0	$103,526	$0
David Craig
Deputy Director of Informatics	$285,763	$0	$288,283	$0	$655	$0	$10,600	$0	$9,931	$0	$595,232	$0	$103,526	$0
James Lowey
Vice President, Technology	$198,763	$0	$0	$0	$725	$0	$7,957	$0	$1,518	$0	$208,963	$0	$0	$0
Daniel Von Hoff
Executive Vice President	$659,337	$0	$150,000	$0	$8,309	$0	$10,600	$0	$6,697	$0	$834,943	$0	$100,000	$0
Patrick Smith
VP, Corporate Development	$290,140	$0	$350,221	$0	$982	$0	$235,658	$0	$8,942	$0	$885,943	$0	$0	$0
Manuel Estrada
Vice President, Finance	$231,741	$0	$0	$0	$895	$0	$7,212	$0	$9,155	$0	$249,003	$0	$0	$0
David Duggan
Associate Professor	$224,819	$0	$0	$0	$756	$0	$9,440	$0	$13,035	$0	$248,050	$0	$0	$0
Michael Bittner
Professor	$218,385	$0	$0	$0	$7,046	$0	$8,657	$0	$7,808	$0	$241,896	$0	$0	$0
James Harris
VP, Business Development	$173,251	$0	$5,000	$0	$40,197	$0	$7,308	$0	$3,853	$0	$229,609	$0	$0	$0
CHARLES K COLESON
CHIEF FINANCIAL OFFICER	$141,107	$0	$15,000	$0	$1,715	$0	$1,924	$0	$50	$0	$159,796	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE J, PART I, LINE 1A	FIRST CLASS TRAVEL IS PERMITTED BY EXECUTIVE STAFF ONLY AND MUST, PER TGEN POLICY, BE PRE-APPROVED BY THE CHIEF OPERATING OFFICER. THESE EXPENSES WERE NOT CONSIDERED AS TAXABLE COMPENSATION TO THE RECIPIENT SINCE THEY WERE REIMBURSEMENTS FOR BUSINESS USE UNDER AN ACCOUNTABLE PLAN.
SCHEDULE J, PART I, LINE 7	SOME OF THE PERSONS LISTED IN FORM 990, PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE BASES, AS APPROVED BY THE TGEN BOARD OF DIRECTORS.
Schedule J, Part II	Charles Coleson received $108,000 in compensation for consulting services provided to TGEN in his capacity as an independent contractor. This amount HAs BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (b)(i) as base compensation. Patrick Smith is eligible to receive $235,658 on 1/29/16 based on reaching strategic objective outlined by management. this amount HAs BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (C) AS DEFERRED COMPENSATION. DEFERRED COMPENSATION INCLUDES RETENTION AGREEMENTS FOR DR. JEFFREY TRENT AND TERESA BURLESON. DR. TRENT IS ELIGIBLE TO RECEIVE $400,000 ON 03/12/2017 AND TERESA BURLESON IS ELIGIBLE TO RECEIVE $250,000 ON 03/31/2020 PAYABLE BY TGEN. AMOUNTS ACCRUED BY TGEN DURING CALENDAR YEAR 2015 UNDER THESE AGREEMENTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (C) AS DEFERRED COMPENSATION AS FOLLOWS: JEFFERY M. TRENT, PH.D. $200,000 TERESA BURLESON $37,500 DANIEL VON HOFF, JOHN CARPTEN AND DAVID CRAIG'S RETENTION AGREEMENTS VESTED ON 11/30/2015. DANIEL VON HOFF RECEIVED $150,000 AND JOHN CARPTEN AND DAVID CRAIG RECEIVED $192,000. TERESA BURLESON RECEIVED $116,667 FROM A RETENTION AGREEMENT IN WHICH SHE VESTED 3/31/2015.

Schedule L IRS990ScheduleL

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Field	Value	IRS element (for citing)
Person	TECH66 LLC WILLIAM BURLESON	PersonNm

Field	Value	IRS element (for citing)
Relationship Description	SPOUSE OF OFFICER	RelationshipDescriptionTxt
Transaction	$115,950	TransactionAmt
Transaction	CONSULTING SERVICES	TransactionDesc
Sharing Of Revenues	false	SharingOfRevenuesInd

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArtGrp
Art Historical Treasures		ArtHistoricalTreasuresGrp
Art Fractional Interest		ArtFractionalInterestGrp
Books And Publications		BooksAndPublicationsGrp
Clothing And Household Goods		ClothingAndHouseholdGoodsGrp
Cars And Other Vehicles		CarsAndOtherVehiclesGrp
Boats And Planes		BoatsAndPlanesGrp
Intellectual Property		IntellectualPropertyGrp
Securities Publicly Traded		SecuritiesPubliclyTradedGrp
Securities Closely Held Stock		SecuritiesCloselyHeldStockGrp
Secur Prtnrshp Trust Intrsts		SecurPrtnrshpTrustIntrstsGrp
Securities Miscellaneous		SecuritiesMiscellaneousGrp
Qualified Contrib Hist Struct		QualifiedContribHistStructGrp
Qualified Contrib Other		QualifiedContribOtherGrp
Real Estate Residential		RealEstateResidentialGrp
Real Estate Commercial		RealEstateCommercialGrp
Real Estate Other		RealEstateOtherGrp
Collectibles		CollectiblesGrp
Food Inventory		FoodInventoryGrp
Drugs And Medical Supplies		DrugsAndMedicalSuppliesGrp
Taxidermy		TaxidermyGrp
Historical Artifacts		HistoricalArtifactsGrp
Scientific Specimens		ScientificSpecimensGrp
Archaeological Artifacts		ArchaeologicalArtifactsGrp

Other Non Cash Contri Table OtherNonCashContriTableGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Desc	COMPUTER EQUIP	Desc
Contribution	1	ContributionCnt
Noncash Contributions Rpt F990	$304,546	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (true)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE M, PART I, COLUMN (B)	FormAndLineReferenceDesc
Explanation	THE ORGANIZATION IS REPORTING IN PART I, COLUMN (B) THE NUMBER OF CONTRIBUTIONS RECEIVED.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (24 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART I, LINE 1 AND PART III, LINE 1	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER DIAGNOSTICS AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES.
FORM 990, PART III, LINE 4A	TGEN'S GENOTYPING TECHNOLOGY CENTER ANALYZES BITS OF DNA CALLED SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) WHICH GIVE RESEARCHERS THE POWER TO IDENTIFY DISEASE-CAUSING GENES, ASSOCIATIONS, AND DNA SIGNATURES, ALL OF WHICH HAVE PROFOUND IMPLICATIONS FOR DETECTION, PROGNOSIS AND THERAPEUTIC INTERVENTION. THE SNPS GENOTYPING CENTER OFFERS INNOVATIVE SOLUTIONS THAT ADDRESS THE REQUIREMENTS FOR FLEXIBILITY, SIMPLICITY, THROUGHPUT, ECONOMY AND ACCURACY.
FORM 990, PART III, LINE 4B	THE NEUROGENOMICS DIVISION HAS TWO GOALS, BOTH OF WHICH DERIVE FROM THE OVERARCHING MISSION OF THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN). IT IS COMMON KNOWLEDGE THAT EARLY INTERVENTION AND TREATMENT SAVES LIVES WHEN IT COMES TO NEUROLOGICAL DISEASES. THEREFORE, OUR FIRST GOAL IS TO IMPROVE THE ABILITY TO DIAGNOSE NEUROLOGICAL DISEASE BEFORE IT STRIKES. BECAUSE THESE DISEASES IMPACT SO MANY LIVES AROUND THE WORLD EITHER DIRECTLY (BY HAVING A DISEASE), OR INDIRECTLY (BY CARING FOR A LOVED ONE WITH A DISEASE), THE SECOND GOAL CENTERS ON THE DEVELOPMENT OF NEW 'SMART-DRUG' THERAPIES. THERE ARE FIVE LABS WITHIN THE DIVISION, ENCOMPASSING THE ENTIRE BREADTH OF NEUROLOGICAL DISEASE.
FORM 990, PART III, LINE 4C	TGEN'S INTEGRATED CANCER GENOMICS DIVISION BRINGS TOGETHER BIOINFORMATICS, CUTTING-EDGE TECHNOLOGIES AND BASIC RESEARCH TO CREATE A COMPREHENSIVE ATTACK ON CANCER WITH THE ULTIMATE GOAL OF DEVELOPING NEW DIAGNOSTICS AND TREATMENTS. SPECIFIC AREAS OF FOCUS INCLUDE PROSTATE CANCER, MELANOMA, FAMILIAL BREAST CANCER, COLON CANCER, MULTIPLE MYELOMA AND RENAL TUMOR RESEARCH. KEEPING IN LINE WITH TGEN'S MISSION OF DEVELOPING EARLIER DIAGNOSTICS AND SMARTER TREATMENTS, WE HOPE THIS INTEGRATED APPROACH TO CANCER GENOME RESEARCH WILL HELP TO UNCOVER IMPORTANT INHERITED AND TUMOR DERIVED ALTERATIONS, WHICH ARE ASSOCIATED WITH CANCER SUSCEPTIBILITY AND IMPORTANT TUMOR CHARACTERISTICS SUCH AS PROGRESSION AND RESPONSE TO THERAPY.
FORM 990, PART III, LINE 4D	INTRODUCTION TGEN CONTINUES TO BE AT THE FOREFRONT OF SCIENTIFIC INNOVATION AND DISCOVERY, USING OUR TECHNOLOGICAL EXPERTISE TO PROVIDE PATIENTS AND THEIR PHYSICIANS WITH THE BEST POSSIBLE INFORMATION TO HELP DIAGNOSE AND TREAT DISEASE. IN 2015, EARLY DETECTION OF DISEASE WAS A MAIN FOCUS OF TGEN INITIATIVES. WE MADE SIGNIFICANT PROGRESS IN THIS AREA OF RESEARCH BY NEARLY ALL MEASURES. ESPECIALLY NOTABLE IS A STUDY THAT ALIGNS OUR MASTERY OF GENE SEQUENCING WITH EFFORTS TO CREATE METHODS OF EARLY DETECTION OF CANCER, AND IN THIS CASE POTENTIALLY THROUGH THE USE OF A SIMPLE BLOOD TEST, OR LIQUID BIOPSY. THE RESULTS OF THIS STUDY, PUBLISHED IN CLINICAL EPIGENETICS, DETAILED THE IDENTIFICATION OF 21 DNA HYPER METHYLATION HOTSPOTS - GENE LOCATIONS ALONG THE 3 BILLION CHEMICAL BASES OF DNA - WITH INCREASED LEVELS OF METHYLATION THAT COULD INDICATE THE EXISTENCE OF METASTATIC BREAST CANCER. THESE FINDINGS COULD LEAD TO A HIGHLY SENSITIVE BLOOD-BASED TEST PANEL (A TYPE OF LIQUID BIOPSY), WHICH COULD HELP IMPROVE THE CARE OF WOMEN WITH BREAST CANCER. THE TEST WOULD LOOK FOR BIOMARKERS DERIVED FROM CELL-FREE STRANDS OF DNA (CFDNA) CIRCULATING IN THE BLOOD. THIS BREAKTHROUGH HAS SIGNIFICANT IMPLICATIONS FOR ALL BREAST CANCER PATIENTS IN THE FUTURE, SINCE ALL SUBTYPES OF BREAST CANCER IN VARYING DEGREES CAN REOCCUR AND METASTASIZE. THIS TEST COULD PROVIDE PHYSICIANS WITH CRITICAL INFORMATION ABOUT THERAPIES, ESPECIALLY FOLLOWING SURGERY OR SESSIONS OF CHEMOTHERAPY. ANOTHER TGEN-LED PROJECT, FUNDED BY THE SEENA MAGOWITZ FOUNDATION AND STAND UP TO CANCER (SU2C), IS ADVANCING TREATMENT OF LATE-STAGE PANCREATIC CANCER PATIENTS THROUGH OUR CLINICAL PARTNERSHIP AT HONORHEALTH (FORMERLY SCOTTSDALE HEALTHCARE). ONE PATIENT WHO ARRIVED AT THE CLINIC LAST APRIL WITH STAGE 4 PANCREATIC CANCER NOW HAS NO DETECTABLE TUMORS, THANKS TO A CLINICAL TRIAL THAT BUILT ON OUR SUCCESS IN TESTING - AND GAINING FDA APPROVAL - OF THE GEMCITABINE/ABRAXANE COMBINATION AS THE NEW STANDARD OF CARE FOR THESE PATIENTS. THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASC0) RECOGNIZED THE GROUNDBREAKING WORK AT TGEN BY INCLUDING AN OVARIAN CANCER STUDY LED BY TGEN PRESIDENT DR. JEFFREY TRENT IN ITS ANNUAL CLINICAL CANCER ADVANCES REPORT, PUBLISHED JAN. 20, IDENTIFYING THE STUDY AS ONE OF THE YEARS TOP RESEARCH PAPERS, WHICH WAS PUBLISHED IN NATURE GENETICS. TGEN WAS ABLE TO IDENTIFY THE LIVELY GENETIC DRIVER OF THIS PARTICULARLY AGGRESSIVE TYPE OF OVARIAN CANCER THAT MOSTLY STRIKES YOUNG WOMEN AND GIRLS. FACULTY WITHIN OUR PATHOGEN GENOMICS DIVISION, TGEN NORTH, PARTICIPATED IN THE DESIGN OF NEW GENOMICS-BASED METHODS FOR ACCURATELY DIAGNOSING VALLEY FEVER AND LYME DISEASE. CREATING A DEFINITIVE, LOW-COST AND ACCURATE DIAGNOSTIC TOOL FOR BOTH DISEASES GREATLY BENEFITS PATIENT HEALTH SINCE SYMPTOMS IN BOTH DISEASES ARE SIMILAR TO OTHER AILMENTS, AND THE CURRENT TESTS ARE SO UNRELIABLE THEY HAVE BEEN COMPARED TO COIN FLIPS. AS A RESULT, BOTH VALLEY FEVER AND LYME DISEASE ARE OFTEN MISDIAGNOSED AND MISTREATED. TGEN NORTHS NEW TESTS WILL CHANGE THAT. A COLLABORATION WITH BAYLOR RESEARCH INSTITUTE (BRI), DALLAS, FOCUSES ON ACCELERATING EARLY DETECTION AND TREATMENTS FOR PATIENTS WITH A BROAD RANGE OF CANCERS. THIS AGREEMENT ALIGNS THE BEST SCIENCE FROM BOTH INSTITUTIONS, LEADING TO NEW CLINICAL TRIALS AND ACCESS TO TECHNOLOGY TO DRIVE THE DEVELOPMENT OF NEW THERAPIES, STARTING AT BAYLOR SCOTT & WHITE HEALTH'S 49 HOSPITALS THROUGHOUT TEXAS. AS A MEASURE OF OUR IMPACT IN THE COMMUNITY, TGEN DISTINGUISHED PROFESSOR AND PHYSICIAN-IN-CHIEF, DR. DANIEL VON HOFF, RECEIVED THE 2015 WALLACE A. REED M.D. AWARD BY THE ARIZONA MEDICAL ASSOCIATION, RECOGNIZING HIS MANY INNOVATIVE CONTRIBUTIONS TO THE ADVANCEMENT OF CANCER CARE, ESPECIALLY IN THE REALM OF PANCREATIC CANCER, ONE OF THE MOST DIFFICULT TO TREAT OF ALL CANCER TYPES. BUILDING ON OUR EXPERTISE WITH HELIOS EDUCATION FOUNDATION IN TRAINING THE NEXT GENERATION OF PHYSICIANS AND RESEARCH SCIENTISTS, WE CONDUCTED A PILOT PROGRAM WITH THE SCOTTSDALE UNIFIED SCHOOL DISTRICT THAT PROVIDES TEACHERS WITH STRONG FLUENCY IN BIOMEDICAL RESEARCH. THE EXCELLENCE IN BIOSCIENCE TEACHER INITIATIVE CONSISTED OF AN INTENSIVE, THREE-DAY SERIES OF PRESENTATIONS, INTERACTIVE DISCUSSIONS AND PRACTICAL EXPERIENCES LED BY TGEN BIO-MEDICAL EXPERTS. IN OCTOBER, THE FOOD AND DRUG ADMINISTRATION (FDA) APPROVED A DRUG, ONIVYDE, FOR ADVANCED PANCREATIC CANCER, BASED ON TGEN-LED RESEARCH AND CLINICAL TRIALS, PROVIDING PATIENTS NEW TREATMENT OPTIONS. BRAIN CANCER RESEARCH, FUNDED BY THE BEN & CATHERINE IVY FOUNDATION, PRODUCED SEVERAL NOTABLE ADVANCEMENTS. ONE TGEN STUDY SHOWED THAT A DRUG, PROPENTOFYLLINE, PREVIOUSLY DEVELOPED FOR DEMENTIA, KNOCKS DOWN A PROTEIN THAT PROMOTES THE SPREAD OF THE BRAIN CANCER GLIOBLASTOMA, INCREASES SENSITIVITY TO A STANDARD CHEMOTHERAPY DRUG, AND INHIBITS GLIOBLASTOMA CELL INVASION. THIS NOW BECOMES A TARGET OF TREATMENT-FOCUSED RESEARCH. NEUROGENOMICS FACULTY ALSO COMPLETED A THIRD SEASON OF A CONCUSSION/BRAIN INJURY STUDY WITH RIDDELL, THE ARIZONA STATE UNIVERSITYS FOOTBALL TEAM - ALONG WITH BARROW NEUROLOGICAL INSTITUTE, AND A.T. STILL UNIVERSITY - TO DISCOVER BIOMARKERS THAT MIGHT INDICATE WHEN AN ATHLETE IS TOO HURT TO PLAY. ADDITIONALLY, THE FOLLOWING SUMMARY PROVIDES A SNAPSHOT OF PROGRESS IN CLINICAL RESEARCH AND CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS, GRANTS, CONTRACTS, PHILANTHROPY, EDUCATION AND OUTREACH, MEDIA AND COMMUNITY RECOGNITION.
CLINICAL RESEARCH AND CLINICAL TRIALS	IN 2015, TGEN ADVANCED A SERIES OF INNOVATIVE RESEARCH INITIATIVES THAT YIELDED NUMEROUS SCIENTIFIC DISCOVERIES (ALL WITH THE POTENTIAL FOR CLINICAL APPLICATION), ESTABLISHED NATIONAL AND INTERNATIONAL COLLABORATIONS, AND LED NEW AND EXCITING CLINICAL TRIALS WITH PROMISING RESULTS. NOTABLE ARE: - IN EARLY MAY, WE ANNOUNCED A COLLABORATION WITH DALLAS, TEXAS-BASED BAYLOR HEALTHCARE AND RESEARCH INSTITUTE FOCUSED ON ACCELERATING EARLY DETECTION AND TREATMENTS FOR PATIENTS WITH A BROAD RANGE OF CANCERS. THIS AGREEMENT FORGES THE BEST SCIENCE OF BOTH INSTITUTIONS, LEADING TO NEW CLINICAL TRIALS AND ACCESS TO TECHNOLOGY TO DRIVE THE DEVELOPMENT OF NEW THERAPIES, STARTING AT BAYLOR SCOTT & WHITE HEALTH'S 49 HOSPITALS THROUGHOUT TEXAS. - THE WEEK PRIOR TO THE TGEN-BAYLOR ANNOUNCEMENT, PREVIOUS COLLABORATIVE WORK BETWEEN OUR INSTITUTIONS LED THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) TO ANNOUNCE THAT A SCIENTIFIC PAPER DESCRIBING POTENTIAL DRUG TARGETS FOLLOWING THE UNPRECEDENTED GENOMIC SEQUENCING OF 14 METASTATIC TRIPLE-NEGATIVE BREAST CANCER PATIENTS WAS THE MOST CITED STUDY IN 2013 OF ANY PUBLISHED THAT YEAR BY AACR'S JOURNAL MOLECULAR CANCER THERAPEUTICS. - IN EARLY NOVEMBER, STAND UP TO CANCER (SU2C) SELECTED DR. VON HOFF AND HIS TEAM TO LEAD ANOTHER PANCREATIC CANCER DREAM TEAM; DR. VON HOFFS SECOND SUCH TEAM (HIS FIRST ACCRUED MORE CANCER PATIENTS ONTO CLINICAL TRIALS THAN ANY DREAM TEAM TO DATE). THIS SELECTION VALIDATES THE SUCCESS THAT DR. VON HOFF AND HIS COLLEAGUES HAVE MADE, AND SIGNIFIES SU2CS BELIEF THAT HIS TEAM OFFERS THE MOST PROMISING NEW APPROACHES TO TREAT PANCREATIC CANCER. THE OVERARCHING AIM FOR THE RESEARCH GRANT IS TO DEVELOP THERAPIES THAT GREATLY IMPROVE A PERSONS SURVIVAL OVER AND ABOVE WHAT DR. VON HOFF AND HIS TEAM HAVE ALREADY ACHIEVED. STAND UP TO CANCER TEAM SCIENCE AWARDS (ALL EXCEEDING 6 MILLION DOLLARS) ARE THE MOST DIFFICULT PEER-REVIEWED SUPPORT TO SECURE IN MEDICAL RESEARCH. DR. JEFFREY TRENT SERVES AS CO-LEADER OF THE MELANOMA DREAM TEAM (JOINTLY SPONSORED BY STAND UP TO CANCER AND THE MELANOMA RESEARCH ALLIANCE). FOR A RESEARCH INSTITUTION TO HAVE TWO OF THE 11 TEAM SCIENCE AWARDS IS A GREAT COMPLIMENT TO THE EXCELLENCE OF TGEN SCIENCE. - THE AVERAGE AGE OF DIAGNOSIS OF OVARIAN CANCER (THE MOST DEADLY FORM OF CANCER IN WOMAN) IS 64 YEARS. BUILDING CLINICALLY ON RESEARCH LED BY TGEN FACULTY, TGEN DEVELOPED A CLINICAL TRIAL FOR PATIENTS FROM AROUND THE WORLD WHO SUFFER FROM THE MOST DEADLY SUB-TYPE OF OVARIAN CANCER, CALLED SMALL CELL CARCINOMA OF THE OVARY (SCCOHT). THIS PARTICULARLY AGGRESSIVE TYPE OF CANCER IS DIAGNOSED AT AN AVERAGE AGE OF 24 YEARS, WITH GIRLS AS YOUNG AS 14 MONTHS DIAGNOSED WITH THIS DISEASE. - ALSO IN A LANDMARK TRIAL, THE SU2C MELANOMA DREAM TEAM DISCUSSED ABOVE (CO-LED BY YALES UNIVERSITIES DR. PAT LORUSSO) ENROLLED ITS FIRST PATIENTS, WITH UP TO ONE HUNDRED MORE PATIENTS WITH THE MOST DEADLY SUB-TYPE OF THIS MELANOMA EXPECTED TO ENROLL OVER THE 18 MONTHS. - WORK SUPPORTED BY THE BEN & CATHERINE IVY FOUNDATION LED TO THREE PROJECTS FOCUSED ON GLIOBLASTOMA. THE FIRST, A SIGNIFICANT AND INNOVATIVE TRIAL WITH COLLEAGUES AT BARROW NEUROLOGICAL INSTITUTE WILL TEST NEW DRUGS IN A PHASE ZERO CLINICAL TRIAL TO DETERMINE IF THEY CAN PENETRATE THE BLOOD-BRAIN BARRIER AND BE EFFECTIVE AGAINST THE TUMOR. ANOTHER DESCRIBED OUR STUDY PUBLISHED IN THE OXFORD UNIVERSITY PRESS JOURNAL NEURO-ONCOLOGY, REVIEWING THE STATE-OF-THE-ART TREATMENTS FOR GLIOBLASTOMA, AND A RELATED CLINICAL TRIAL AT UC SAN FRANCISCO. AND THE THIRD, WORK WITH THE ALLEN BRAIN INSTITUTE IN SEATTLE, WASHINGTON, TO UPDATE THE IVY GLIOBLASTOMA ATLAS PROJECT. - TECHNOLOGY ADVANCEMENTS IN RECENT YEARS NOW ALLOW TGEN AND OTHER SCIENTISTS TO LOOK DEEPER INTO THE HUMAN GENOME THAN EVER BEFORE, WHICH HAS FURTHERED THE RESEARCH OF SEVERAL FACULTY MEMBERS INTO SO-CALLED LIQUID BIOPSIES - MORE OR LESS AN ADVANCED BLOOD TEST - FOR DETECTING THE SMALLEST OF CANCER CELLS (OR THE CONTENT OF THOSE CANCER CELLS) SWIMMING IN A PERSONS BLOOD, LOOKING FOR A SPOT TO TAKE ROOT AND BECOME A FULL-BLOWN TUMOR. - FINALLY, A HOST OF OUR SCIENTISTS INCLUDING DRS. CRAIG AND HUENTLEMAN, JOIN OUR CLINIC LEADER (DR. NARAYANAN) IN THEIR FOCUS ON CHILDREN WITH RARE OR UNDIAGNOSED DISORDERS TO PROVIDE HOPE AND ANSWERS TO PARENTS WHO ENDURE DIAGNOSTIC ODYSSEYS THAT AT TIMES SPAN MULTIPLE YEARS.
PEER REVIEWED LABORATORY RESEARCH PUBLICATIONS AND PRESENTATIONS	SINCE DAY ONE, THE FOCUS OF OUR TRANSLATIONAL RESEARCH HAS CONSTANTLY REMAINED THE PATIENT; THOSE INDIVIDUALS WITH CANCER, ALZHEIMERS AND OTHER NEUROLOGICAL DISORDERS, AND A HOST OF RARE DISEASES THAT ALL TOO OFTEN GO MIS- OR UNDIAGNOSED. IN JANUARY, DURING HIS STATE-OF-THE-UNION ADDRESS, PRESIDENT OBAMA SAID THAT PERSONALIZED MEDICINE "GIVES US ONE OF THE GREATEST OPPORTUNITIES FOR NEW MEDICAL BREAKTHROUGHS THAT WE HAVE EVER SEEN." WHILE MANY INSTITUTES AND HEALTHCARE NETWORKS HAVE TAKEN UP THE CHARGE OF LATE, TGEN HAS PUSHED THE BOUNDARIES OF THIS SPACE FOR THE PAST DECADE. MUCH OF WHAT WE LEARN IS PUBLISHED IN LEADING SCIENTIFIC AND MEDICAL JOURNALS, WHICH INCREASES THE KNOWLEDGE BASE OF ALL THOSE IN THE BIOMEDICAL RESEARCH AND MEDICAL SPACE. OUR ANNUAL SCIENTIFIC RETREAT IN OCTOBER BROUGHT TOGETHER NEARLY 240 REGISTRANTS INCLUDING TGEN FACULTY, STAFF, STUDENTS AND 45 COLLABORATORS. TGEN SCIENTISTS PRESENTED OVER 60 SCIENTIFIC POSTERS, EIGHT UNIQUE BREAKOUT PANELS AND FOUR COMPETITIVELY SELECTED "HOT TOPICS" PRESENTATIONS. THE PURPOSE OF THE EVENT WAS TO SUMMARIZE THE INSTITUTES SCIENTIFIC YEAR AND CREATE AN ENVIRONMENT IN WHICH NEW PROFESSIONAL RELATIONSHIPS AND COLLABORATIONS, BOTH INTERNAL AND EXTERNAL, COULD DEVELOP. IN 2015, TGEN RESEARCHERS PUBLISHED THEIR RESEARCH RESULTS EXTENSIVELY IN NUMEROUS SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND THROUGH PRESENTATIONS AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES. THESE INCLUDE PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS SCIENCE ADVANCES, PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES, USA, CELL, NATURE COMMUNICATIONS, MOLECULAR CANCER THERAPEUTICS, NERO ONCOLOGY, PLOS ONE, GENOME RESEARCH, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, NEUROLOGY, AND A HOST OF OTHER DISEASE-ASSOCIATED PUBLICATIONS. 2015 HIGHLIGHTS A) DESMOPLASIA IN PRIMARY TUMORS AND METASTATIC LESIONS OF PANCREATIC CANCER. CLIFFORD J WHATCOTT, CAROLINE H DIEP, PING JIANG, APRILL WATANABE, JANINE LOBELLO, CHAO SIMA, GALEN HOSTETTER, H. MICHAEL SHEPARD, DANIEL D. VON HOFF, AND HAIYONG HAN. FEBRUARY 18, 2015. B) REVIEW OF X-LINKED SYNDROMES WITH ARTHROGRYPOSIS OR EARLY CONTRACTURES-AID TO DIAGNOSIS AND PATHWAY IDENTIFICATION. HUNTER JM1, KIEFER J, BALAK CD, JOOMA S, AHEARN ME, HALL JG, BAUMBACH-REARDON L. AM J MED GENET A. 2015 MAY; 167(5):931-73. EPUB 2015 MAR 19. C) NOVEL PATHOGENIC VARIANTS AND GENES FOR MYOPATHIES IDENTIFIED BY WHOLE EXOME SEQUENCING. HUNTER JM, AHEARN ME, BALAK CD, LIANG WS, KURDOGLU A, CORNEVEAUX JJ, RUSSELL M, HUENTELMAN MJ, CRAIG DW, CARPTEN JD, COONS SW, DEMELLO DE, HALL JG, BERNES SN AND BAUMBACH-REARDON L. MOLECULAR GENETICS & GENOMIC MEDICINE. VOLUME 3, ISSUE 4, PAGES 283301. ARTICLE FIRST PUBLISHED ONLINE APRIL 8, 2015. D) TOWARDS PRECISION MEDICINE IN GLIOBLASTOMA: THE PROMISE AND THE CHALLENGES. MICHAEL D. PRADOS, SARA A. BYRON, NHAN L. TRAN, JOANNA J. PHILLIPS, ANNETTE M. MOLINARO, KEITH L. LIGON, PATRICK Y. WEN, JOHN G. KUHN, INGO K. MELLINGHOFF, JOHN F. DE GROOT, HOWARD COLMAN, TIMOTHY F. CLOUGHESY, SUSAN M. CHANG, TIMOTHY C. RYKEN, WAIBHAV D. TEMBE, JEFFREY A. KIEFER, MICHAEL E. BERENS, DAVID W. CRAIG, JOHN D. CARPTEN AND JEFFREY M. TRENT. NEURO ONCOL (2015) DOI: 10.1093/NEUONC/NOV031 FIRST PUBLISHED ONLINE: MAY 1, 2015. E) STAPHYLOCOCCUS AUREUS AND THE ECOLOGY OF THE NASAL MICROBIOME. CINDY M. LIU, LANCE B. PRICE, BRUCE A. HUNGATE, ALISON G. ABRAHAM, LISBETH A. LARSEN, KAARE CHRISTENSEN, MARC STEGGER, ROBERT SKOV, PAAL SKYTT ANDERSEN. SCIENCE ADVANCES. 05 JUN 2015, VOL. 1, NO. 5. F) PHYLOGENETICALLY TYPING BACTERIAL STRAINS FROM PARTIAL SNP GENOTYPES OBSERVED FROM DIRECT SEQUENCING OF CLINICAL SPECIMEN METAGENOMIC DATA. SAHL JW, SCHUPP JM, RASKO DA, COLMAN RE, FOSTER JT, KEIM P. GENOME MED. 2015 JUN 9;7(1):52. G) ORCHESTRATING THE TUMOR MICROENVIRONMENT TO IMPROVE SURVIVAL FOR PATIENTS WITH PANCREATIC CANCER: NORMALIZATION, NOT DESTRUCTION. WHATCOTT CJ, HAN H, VON HOFF DD. CANCER J. 2015 JUL-AUG; 21(4): 299-306. H) PILOT TRIAL OF SELECTING MOLECULARLY GUIDED THERAPY FOR PATIENTS WITH NON-V600 BRAF-MUTANT METASTATIC MELANOMA: EXPERIENCE OF THE SU2C/MRA MELANOMA DREAM TEAM. LORUSSO PM, BOERNER SA, PILAT MJ, FORMAN KM, ZUCCARO CY, KIEFER JA, LIANG WS, HUNSBERGER S, REDMAN BG, MARKOVIC SN, SEKULIC A, BRYCE AH, JOSEPH RW, COWEY CL, FECHER LA, SOSMAN JA, CHAPMAN PB, SCHWARTZ GK, CRAIG DW, CARPTEN JD, TRENT JM. MOL CANCER THER. 2015 AUG; 14(8): 1962-71. EPUB 2015 JUN 10. I) WHOLE-GENOME BISULFITE SEQUENCING OF CELL-FREE DNA IDENTIFIES SIGNATURE ASSOCIATED WITH METASTATIC BREAST CANCER. LEGENDRE C, GOODEN GC, JOHNSON, MARTINEZ RA, LIANG WS AND SALHIA B. CLINICAL EPIGENETICS 2015, 7:100. SEPTEMBER 16, 2015. J) BRINGING RNA-SEQ CLOSER TO THE CLINIC. VAN KEUREN-JENSEN K, KEATS JJ, CRAIG DW. NAT BIOTECHNOL. 2014 SEP; 32(9):884-5. K) MULTIFOCAL CLONAL EVOLUTION CHARACTERIZED USING CIRCULATING TUMOR DNA IN A CASE OF METASTATIC BREAST CANCER. MUHAMMED MURTAZA, SARAH-JANE DAWSON, KATHERINE POGREBNIAK, OSCAR M. RUEDA, ELENA PROVENZANO, JOHN GRANT, SUET-FEUNG CHIN, DANA W. Y. TSUI, FRANCESCO MARASS, DAVINA GALE, H. RAZA ALI, PANKTI SHAH, TANIA CONTENTE-CUOMO, HOSSEIN FARAHANI, KAREY SHUMANSKY, ZOYA KINGSBURY, SEAN HUMPHRAY, DAVID BENTLEY, SOHRAB P. SHAH, MATTHEW WALLIS, NITZAN ROSENFELD & CARLOS CALDAS. NATURE COMMUNICATIONS 6, ARTICLE NUMBER: 8760. L) RARE VARIANTS IN CARDIOMYOPATHY GENES ASSOCIATED WITH STRESS-INDUCED CARDIOMYOPATHY. KALANI MY, SINIARD AL, CORNEVEAUX JJ, BRUHNS R, RICHHOLT R, FORSETH J, ZABRAMSKI JM, NAKAJI P, SPETZLER RF, HUENTELMAN MJ. NEUROSURGERY. 2015 NOV 24.
GRANT SUPPORT	IN ADDITION TO PHILANTHROPIC DONATIONS AND RESEARCH CONTRACTS, GRANT FUNDING IS AN IMPORTANT FUNDING SOURCE FOR RESEARCH. TO DATE IN 2015, TGEN INVESTIGATORS SUBMITTED 97 GRANTS TOTALING $84M. TO DATE IN 2015, TGEN WAS AWARDED 20 GRANTS, TOTALING $5.7M, WITH AN ADDITIONAL 12 GRANTS PENDING AWARD TOTALING $3.6M AND 54 GRANTS UNDER REVIEW TOTALING $35M. TGENS SUCCESS RATE HAS CONSISTENTLY MET OR EXCEEDED THE NATIONAL AVERAGE AS CALCULATED BY THE NIH. IN 2015, TGENS CUMULATIVE SUCCESS RATE OF 22%, WAS SLIGHTLY HIGHER THAN THE NATIONAL AVERAGE. 2015 highlights A SELECTION OF AWARDS INCLUDE: A) THREE-YEAR STAND UP TO CANCER GRANT TOTALING $12M TO DR. VON HOFF TO DEVELOP THERAPIES THAT IMPROVE SURVIVAL OF PATIENTS WITH PANCREATIC CANCER. B) FIVE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $1,665,818 TO DR. MATT HUENTELMAN TO STUDY NEURAL SYSTEM DYNAMICS AND GENE EXPRESSION SUPPORTING SUCCESSFUL COGNITIVE AGING. C) FIVE-YEAR GRANT FROM NIH TOTALING $778,502 TO DR. MATT HUENTELMAN TO STUDY EPIGENETIC, NEUROIMAGING AND BEHAVIORAL EFFECTS OF HYPERTENSION IN THE AGING BRAIN. D) TWO-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $735,851 TO DR. PATRICK PIRROTTE TO STUDY PRESERVATION OF DRIED PLASMA SPOTS FOR DOWNSTREAM PROTEOMIC APPLICATIONS. E) FOUR-YEAR GRANT FROM NIH TOTALING $471,542 TO DR. MATT HUENTELMAN TO STUDY A CELL ACTIVITY TAGGING TOOLBOX, ALSO KNOW AS CATT, TO BETTER UNDERSTAND DEVELOPMENT AND APPLICATION OF NEURONAL CELL ACTIVITY. F) ONE-YEAR GRANT FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION TOTALING $339,997 TO DR. PAUL KEIM TO STUDY DNA SEQUENCING AND BIOINFORMATICS ANALYSIS OF PATHOGENS WITH IMP. G) ONE-YEAR GRANT FROM THE ARIZONA BIOMEDICAL RESEARCH COMMISSION TOTALING $225,000 TO DR. JESSE HUNTER TO STUDY IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF NOVEL NEUROMUSCULAR DISEASE CAUSING VARIANTS IN ARIZONA INFANTS AND CHILDREN. H) TWO-YEAR GRANT FROM THE AVON FOUNDATION TOTALING $200,006 TO DR. BODOUR SALHIA TO STUDY THE DEVELOPMENT OF NOVEL TARGETED THERAPEUTIC APPROACHES FOR BREAST CANCER METASTASIS TO THE BRAIN. I) TWO-YEAR GRANT FROM SCIENCE FOUNDATION ARIZONA TOTALING $200,000 TO DR. JEFFREY TRENT ON BEHALF OF DR. MUHAMMAD MURTAZA TO STUDY THE FUTURE OF TRANSLATIONAL RESEARCH. J) TWO-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TOTALING $176,403 TO DR. DAVID CRAIG TO STUDY SOMATIC MUTATIONS IN THE BRAIN DURING ALZHEIMERS DISEASE. K) TWO-YEAR GRANT FROM THE DEPARTMENT OF DEFENSE TOTALING $73,654 TO DR. KENDALL VAN-KEUREN JENSEN TO STUDY EXOSOME-MEDIATED TRANSMISSION OF NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS). L) TWO-YEAR GRANT FROM THE NATIONAL FOUNDATION FOR CANCER RESEARCH TOTALING $300,002 TO DRS. DANIEL VON HOFF AND HAIYONG HAN TO STUDY A NOVEL APPROACH TO TARGETING CANCER CELLS THROUGH MODULATING GLOBAL GENE TRANSCRIPTION USING SUPER-ENHANCER (SE) INHIBITORS. M) ONE-YEAR GRANT FROM THE ARIZONA ALZHEIMERS RESEARCH CONSORTIUM TOTALING $205,000 TO DR. MATT HUENTELMAN FOR FOUR PROJECTS INVOLVING "EXCEPTIONAL" PHENOTYPES, THE DYRK1A GENE, VALIDATION OF RNA TARGETS IN SERUM AND CSF AND CHARACTERIZATION OF MITOCHONDRIAL PSEUDOGENES IN ALZHEIMERS DISEASE. N) THREE-YEAR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) TOTALING $2,062,360 TO DR. KENDALL VAN KEUREN-JENSEN AND DR. MATT HUENTELMAN FOR A STUDY OF BIOMARKERS THAT COULD PREDICT PATIENT OUTCOMES, FOLLOWING INJURIES THAT RESULT IN BLEEDING IN THE BRAIN. O) FIVE-YEAR GRANT FROM NIH TOTALING $1,033,331 TO DR. NHAN TRAN TO STUDY THE NOVEL ROLE OF TROY-EGFR GENE COMPLEX IN GLIOBLASTOMA BRAIN TUMOR INVASION AND RESISTANCE. P) TWO-YEAR GRANT FROM THE NIH TOTALING $487,540 TO DR. MATT HUENTELMAN FOR A STUDY IDENTIFYING PATHOGENIC MECHANISMS IMPORTANT IN MULTIPLE SYSTEM ATROPHY (MSA), FOR WHICH THERE CURRENTLY ARE NO DISEASE PREVENTING OR MODIFYING TREATMENTS. Q) TWO-YEAR GRANT FROM NIH/NATIONAL CANCER INSTITUTE TOTALING $445,005 TO DR. HAIYONG HAN FOR A STUDY TARGETING THE PHD2 GENE IN PANCREATIC CANCER. R) ONE-YEAR GRANT FROM THE CENTERS FOR DISEASE CONTROL TOTALING $347,043 TO DR. PAUL KEIM FOR DNA SEQUENCING AND BIOINFORMATICS ANALYSIS OF PATHOGENS, INCLUDING EMERGENCY RESPONSE AS NEEDED FOR DISEASE OUTBREAK.
ENTERPRISE EFFORTS, COLLABORATION, SPIN-OFFS AND JOB CREATION	THE TECHNOLOGY TRANSFER OFFICE (TTO) FACILITATES AND ACCELERATES THE COMMERCIALIZATION OF TGEN'S SCIENTIFIC DISCOVERIES FOR THE BENEFIT OF HUMAN HEALTH BY, - IDENTIFYING, PATENTING AND LICENSING NEW TECHNOLOGY; - FACILITATING ACCESS AND EXCHANGE OF RESEARCH MATERIALS, TECHNOLOGIES, AND DATA VIA MATERIAL TRANSFER AGREEMENTS (MTAS) OR CONFIDENTIAL DISCLOSURE AGREEMENTS (CDAS); - NEGOTIATING COLLABORATIVE RESEARCH AGREEMENTS; AND - ASSISTING IN THE FORMATION OF START-UP COMPANIES WHEN APPROPRIATE. DURING 2015, TGEN CONTINUED COLLABORATIONS WITHIN THE STATE OF ARIZONA, INCLUDING NEW JOINT FACULTY WITH MAYO CLINIC. Invention disclosures TGEN RECEIVED 18 INVENTION DISCLOSURES BASED ON DISCOVERIES STEMMING FROM TGEN-LED RESEARCH, AND FILED 19 PROVISIONAL PATENT APPLICATIONS. Contracts and collaborations TGEN SIGNED A TOTAL OF 358 CONTRACTS/AMENDMENTS IN 2015, BROKEN DOWN AS FOLLOWS: A) 65 CDAS B) 66 MTAS C) 18 RESEARCH COLLABORATIONS D) 15 MASTER RESEARCH/SERVICES AGREEMENTS E) 44 RESEARCH PLANS AND SOWS F) 23 CONSULTING AGREEMENTS G) 62 PROFESSIONAL SERVICE AGREEMENTS H) 02 COMMERCIALIZATION LICENSES I) 63 AGREEMENTS COVERING MISCELLANEOUS ACTIVITIES A LISTING OF A NUMBER OF THE MAJOR RESEARCH COLLABORATORS INCLUDE: ALLINA HEALTH/JNNI; BAYLOR RESEARCH INSTITUTE; BROAD INSTITUTE; COLORADO STATE UNIVERSITY; DIGNITY; FLORIDA INSTITUTE FOR HUMAN & MACHINE COGNITION; GEORGE MASON UNIVERSITY; HONORHEALTH; MAYO CLINIC; MIDWESTERN UNIVERSITY; NATIONAL CENTER FOR ADVANCING TRANSLATION SCIENCES; OHIO STATE UNIVERSITY; ST. ANNES UNIVERSITY HOSPITAL. Job creation IN 2015, 21 NEW FULL-TIME EQUIVALENT POSITIONS WERE CREATED WITH SALARIES AND BENEFITS TOTALING $1,205,184. SALARIES FOR TEMPORARY POSITIONS (THOSE POSITIONS CREATED FOR A FINITE PERIOD OF TIME) TOTALED $99,120, WHICH INCLUDES TEMPORARY TGEN STAFF AND TEMPORARY SERVICE FEES. STUDENT SALARIES WERE JUST OVER $460,000, BRINGING THE OVERALL 2015 TOTAL TO $1,665,184. IN TERMS OF EDUCATION LEVEL, EIGHTY-SIX PERCENT OF FULL-TIME TGEN STAFF HOLDS A COLLEGE DEGREE AND FIFTY PERCENT HOLDS AN ADVANCED DEGREE. 2015 FULL-TIME POSITIONS FILLED (NEW AND REPLACEMENTS) INCLUDED: - ASSOCIATE BIOINFORMATICIAN - ASSISTANT PROFESSOR - BIOINFORMATICIAN - CLINICAL RESEARCH COORDINATOR - FINANCIAL ANALYST II - CONTRACTS MANAGER - FACILITIES TECHNICIAN - POST-DOC FELLOW - RESEARCH ASSISTANT PROFESSOR - RESEARCH ASSOCIATE - RESEARCH ASSOCIATE II - RESEARCH TECHNICIAN - SR. GRANTS ADMINISTRATOR - SR. STAFF SCIENTIST - SR. VICE PRESIDENT, EMERGING OPPORTUNITIES
EDUCATION	TGEN DESIGNED ITS SCIENCE EDUCATION AND COMMUNITY OUTREACH INITIATIVES TO ASSIST IN THE GROWTH OF THE BIOSCIENCE WORKFORCE IN ARIZONA, INCREASE PUBLIC FLUENCY IN TRANSLATIONAL MEDICINE, AND BUILD AN ACCESSIBLE COMMUNITY PRESENCE. 2015 HIGHLIGHTS INCLUDE: NEARLY 600 ARIZONA STUDENTS APPLIED TO THE 2015 HELIOS SCHOLARS AT TGEN PROGRAM, WITH 45 SELECTED TO WORK FULL-TIME ALONGSIDE A TGEN MENTOR TO DEVELOP AND ENHANCE THEIR SKILLS BY CONTRIBUTING TO AN AUTHENTIC BIOMEDICAL RESEARCH PROJECT. IN TERMS OF 2015 COHORT DEMOGRAPHICS, 69 PERCENT ATTEND COLLEGES OR UNIVERSITIES IN ARIZONA; 27 PERCENT SELF-IDENTIFY AS RACES/ETHNICITIES UNDERREPRESENTED IN THE BIOSCIENCES; 11 PERCENT ATTEND HIGH SCHOOL, 87 PERCENT ARE WORKING TOWARD AN UNDERGRADUATE DEGREE AND 2 PERCENT ATTEND GRADUATE OR MEDICAL SCHOOL. TGEN ENGAGED OVER 60 HELIOS SCHOLARS ALUMNI FOR THE FOURTH ANNUAL ALUMNI NETWORKING RECEPTION. ALUMNI PROVIDED GUIDANCE TO THIS SUMMERS INTERN CLASS VIA A PANEL DISCUSSION AND PARTICIPATED IN THE SELECTION PROCESS. NETWORKING OPPORTUNITIES ENSURE THE PROGRAM CONTINUES TO DELIVER ON THE MISSION TO GROW THE BIOSCIENCE WORKFORCE IN ARIZONA. THE 2015-2016 IVY NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM BEGAN IN JUNE. TWO HIGH SCHOOL STUDENTS COMPLETED BRAIN TUMOR AND NEUROLOGICAL DISEASE RESEARCH INTERNSHIPS IN JULY. TWO UNDERGRADUATES AND ONE MEDICAL SCHOOL STUDENT WILL BEGIN IN SEPTEMBER. AT THE CONCLUSION OF THIS YEARS PROGRAM, 22 ARIZONA STUDENTS WILL HAVE COMPLETED PROFESSIONAL DEVELOPMENT AND INTENSIVE RESEARCH TRAINING IN BRAIN TUMORS AND NEUROLOGICAL DISEASE. THE PROGRAM CONTINUES TO BE A HIGH-CALIBER SUCCESS IN WORKFORCE DEVELOPMENT AND PRODUCTIVE RESEARCH, RESULTING FROM THE GENEROSITY OF THE BEN AND CATHERINE IVY FOUNDATION. IN ADDITION TO ITS ANNUAL HELIOS SCHOLARS AND IVY PROGRAMS, TGEN BROADENED THE SCOPE OF DIVERSITY IN STUDENT INTERN EXPERIENCES BY HOSTING A STUDENT INTERN FROM A PUBLIC AND HISTORICALLY BLACK UNIVERSITY, NORTH CAROLINA CENTRAL UNIVERSITY, PART OF THE UNIVERSITY OF NORTH CAROLINA SYSTEM. ADDITIONALLY, TGEN RESEARCHERS MENTORED TWO BASIS SCHOOLS STUDENTS, AND HOSTED THREE ACADEMIC YEAR INTERNS SUPPORTED BY ARIZONA COMMUNITY FOUNDATION FUNDING. WITH AN AWARD OF $25,000 FROM THE SCOTTSDALE UNIFIED SCHOOL DISTRICT FOUNDATION, TGEN CONDUCTED A TEACHER TRAINING PILOT PROGRAM IN JULY WITH SAGUARO HIGH SCHOOL, A MAGNET MATH AND SCIENCE ACADEMY IN THE SCOTTSDALE UNIFIED SCHOOL DISTRICT. THE PURPOSE OF THE THREE-DAY, FIVE-TEACHER PROGRAM WAS TO INCREASE THE TEACHERS CONTENT KNOWLEDGE, DEPTH OF UNDERSTANDING AND INSIGHT INTO BIOMEDICAL RESEARCH, BENEFITTING AN EXPONENTIAL NUMBER OF ARIZONA STUDENTS OVER TIME. AN INTENSIVE AGENDA IMMERSED TEACHERS IN A SERIES OF PRESENTATIONS, INTERACTIVE DISCUSSIONS AND PRACTICAL EXPERIENCES LED BY TGEN FACULTY AND STAFF. THE PROGRAM PROVIDED PROOF-OF-CONCEPT FOR THE POSSIBILITY OF A FUTURE STATEWIDE TEACHER PROFESSIONAL DEVELOPMENT INITIATIVE THAT WILL ENHANCE TGENS REPUTATION AS A COMMITTED EDUCATION STAKEHOLDER IN ARIZONA. PROGRAM FEEDBACK WAS OVERWHELMINGLY POSITIVE. TGEN ASSISTED THE FLINN FOUNDATION WITH PILOTING A NEW INTERNSHIP PROGRAM AS PART OF ITS WORKFORCE DEVELOPMENT INITIATIVE, THE FLINN SCHOLARS PROGRAM. AN ARIZONA STATE UNIVERSITY FLINN SCHOLAR FOCUSED ON THE BUSINESS OF SCIENCE WORKING ALONGSIDE TGENS BUSINESS DEVELOPMENT TEAM. TGEN STAFF TRAVELED TO PITTSBURGH TO VOLUNTEER AND COLLECT DATA AT THE 2015 INTEL ISEF, THE INTERNATIONAL HIGH SCHOOL SCIENCE FAIR, WHICH IS THE LARGEST IN THE WORLD. THE INTEL ISEF WILL RETURN TO PHOENIX IN 2016 AND 2019. TGEN STAFF PARTICIPATES ON THE LOCAL ARRANGEMENTS COMMITTEE AND JUDGE RECRUITMENT COMMITTEE TO ENSURE THE THOUSANDS OF INDIVIDUALS ATTENDING THE FAIR FROM NEARLY 70 COUNTRIES EXPERIENCE PHOENIX AND TGEN IN A POSITIVE WAY. LASTLY, TGEN STAFF PARTICIPATED IN AN UPDATE OF THE BIOSCIENCE STANDARDS FOR THE ARIZONA DEPARTMENT OF EDUCATION CAREER AND TECHNICAL EDUCATION VIA THE VALIDATION COMMITTEE. THE GOAL OF PARTICIPATION WAS TO PROVIDE EXPERT INSIGHT INTO THE TECHNICAL KNOWLEDGE AND SKILLS HIGH SCHOOL STUDENTS NEED TO BE PREPARED TO ENTER THE BIOSCIENCE WORKFORCE.
PUBLIC OUTREACH	IN 2015, TGEN HOSTED OVER 800 INDIVIDUALS FOR LABORATORY TOURS, AN INCREASE OF NEARLY 40 PERCENT OVER 2014. TGEN IS COMMITTED TO MAINTAINING AN ACCESSIBLE COMMUNITY PRESENCE FOR THE PUBLIC, SCHOOL GROUPS, LEADERS AND INTERESTED INDIVIDUALS. TGEN BELIEVES IT HAS A RESPONSIBILITY TO OFFER WORKFORCE DEVELOPMENT KNOWLEDGE, CONTENT AND EXPERTISE TO OUR EDUCATION COMMUNITY PARTNERS. IN THIS SPIRIT, TGEN IS REPRESENTED ON BOARDS, COMMITTEES AND WORKING GROUPS INCLUDING, BUT NOT LIMITED TO: CENTER FOR RESEARCH IN ENGINEERING, SCIENCE AND TECHNOLOGY (CREST) SCHOOL ADVISORY BOARD; ARIZONA BIOINDUSTRY ASSOCIATION EVENTS AND EDUCATION COMMITTEE; CITY OF PHOENIX HEALTHCARE SECTOR PARTNERSHIP; ARIZONA BIOMEDICAL RESEARCH COMMISSION; CENTRAL PHOENIX WOMEN; DEER VALLEY UNIFIED SCHOOL DISTRICT CAREER AND TECHNICAL EDUCATION BOARD; TEMPE UNIFIED HIGH SCHOOL DISTRICT CAREER AND TECHNICAL EDUCATION BOARD; QUEEN CREEK HIGH SCHOOL BIOTECHNOLOGY ADVISORY PANEL; PEORIA UNIFIED MEDICAL, ENGINEERING AND TECHNOLOGY PROFESSIONAL ACADEMY ADVISORY TEAM. IN MARCH 2015, TGEN HOSTED TWO PHOENIX HIGH SCHOOL STUDENTS FOR THE BE A LEADER FOUNDATIONS ANNUAL SHADOW A PROFESSIONAL DAY. TGEN HAS PARTICIPATED IN THIS EVENT EVERY YEAR FOR MORE THAN FIVE YEARS. THE MISSION OF THE BE A LEADER FOUNDATION IS TO DESIGN PROGRAMS THAT INSTILL A HIGH SCHOOL COMPLETION AND COLLEGE-GOING CULTURE FOR LOCAL STUDENTS. IN SUPPORT OF THE ARIZONA SCITECH FESTIVAL, TGEN PARTNERED WITH START@WEST-MEC, A COLLABORATIVE EDUCATION SPACE AT THE WESTERN MARICOPA EDUCATION CENTER, TO DELIVER TEACHER PROFESSIONAL DEVELOPMENT IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY. TGEN SELECTED THIS PARTNER TO INCREASE ACCESS TO TGEN PROFESSIONAL DEVELOPMENT FOR WEST VALLEY EDUCATORS. ABOUT 20 TEACHERS ATTENDED TO INTERACT WITH A PANEL OF TGEN RESEARCHERS AND STUDENT INTERNS.
MEDIA, MARKETING AND PUBLIC RECOGNITION	THE OVERALL GOAL OF TGENS MEDIA EFFORTS IS TO BUILD A STRONG AND COMPELLING COMMUNICATIONS TOOL SET TO TELL TGENS STORY IMMEDIATELY TO AUDIENCES THAT, OVER TIME, WILL BE INCREASINGLY AWARE OF TGEN AND WHAT MAKES IT UNIQUE AND ESSENTIAL. TO THE END, TGEN CONTINUALLY PURSUES EARNED MEDIA EXPOSURE FOR THE INSTITUTES RESEARCH ACTIVITIES. 2015 ALSO MARKED TGENS ENGAGEMENT IN PAID MEDIA TO DRIVE TRAFFIC THROUGH ITS VARIOUS SOCIAL CHANNELS. IN TERMS OF OUR SOCIAL PLATFORMS, WE SAW A 27.5% INCREASE ON FACEBOOK; 34.5% ON TWITTER; 94.5% ON LINKEDIN, AND OUR E-NEWS IS NOW SENT TO OVER 12,000 SUBSCRIBERS/DONORS. OUR EARNED MEDIA EFFORTS CONTINUE TO RECEIVE POSITIVE PRESS, BOTH LOCALLY AND NATIONALLY, TOTALING NEARLY 1,000 IMPRESSIONS ACROSS VARIOUS PRINT, BROADCAST AND DIGITAL PLATFORMS, INCLUDING: FORBES MAGAZINE, NEWSWEEK, THE ARIZONA REPUBLIC, PITTSBURGH POST-GAZETTE, SAN ANGELO STANDARD-TIMES (TEXAS), GENOMEWEB, PHOENIX BUSINESS JOURNAL, ARIZONA BUSINESS GAZETTE, THE ARIZONA DAILY SUN (FLAGSTAFF), ABC 15, FOX 10, CBS 5, ARIZONA FAMILY CHANNEL 3, KJZZ, KFYI, KTAR, CHANNEL 8 PBS PHOENIX, CHANNEL 6 PBS TUCSON, ARIZONA REDBOOK, ARIZONA FOOTHILLS MAGAZINE, ARIZONAS VOICE, MAGAZINE, DRUG DELIVERY: SURVEYING THE GLOBAL COMPETITIVE LANDSCAPE, STATES NEWS SERVICE, TARGETED NEWS SERVICE, PLUS PATENT NEWS, PRWEB NEWSWIRE, WEB NEWSWIRE, VIRTUAL STRATEGY MAGAZINE, US FED NEWS, US OFFICIAL NEWS. IN TERMS OF PUBLIC RECOGNITION, TGEN FACULTY AND LEADERSHIP PARTICIPATED IN NUMEROUS COMMUNITY ACTIVITIES AND SERVE ON MANY BOARDS. RECOGNITION OF TGENS EFFORTS SERVES TO HIGHLIGHT OUR PUBLIC, ACADEMIC AND INDUSTRY INVOLVEMENT ACROSS ARIZONA. IN 2015, RECOGNITION INCLUDED: IN MARCH, THE PHOENIX BUSINESS JOURNAL NAMED TGEN COO TESS BURLESON AS ONE OF THE PHOENIX BUSINESS JOURNALS 2015 OUTSTANDING WOMEN IN BUSINESS. THE AWARD HONORS REMARKABLE WOMEN IN THE VALLEY BUSINESS COMMUNITY WHO SERVE AS MENTORS, LEADERS AND VISIONARIES. TGEN ASSOCIATE PROFESSOR DR. MATT HUENTELMAN DELIVERED THE KEYNOTE PRESENTATION AT THE ANNUAL ARIZONA BIOINDUSTRY ASSOCIATION EXPO IN APRIL. DR. HUENTELMAN DISCUSSED HOW TGEN'S MINDCROWD PROGRAM IS A PRIME EXAMPLE OF USING ONLINE CROWDSOURCING TO RECRUIT VOLUNTARY INDIVIDUALS FOR SCIENTIFIC STUDIES AND CLINICAL RESEARCH TO AN AUDIENCE OF BIOSCIENCE INDUSTRY LEADERS, STATE AND CITY OFFICIALS AND STUDENTS. TGEN DIRECTOR OF PUBLIC AFFAIRS AND EDUCATION, BRANDY WELLS, WAS APPOINTED BY GOVERNOR DOUG DUCEY TO THE ARIZONA BIOMEDICAL RESEARCH COMMISSION AND CONFIRMED BY THE ARIZONA SENATE TO SERVE A THREE-YEAR TERM AS A PUBLIC MEMBER COMMISSIONER.
Form 990, Part IV, Line 32b	The organization did not sell, exchange, dispose of, or transfer more than 25% of its net assets. However, due to a significant decrease in PMeds financial position and continued operating losses, TGen recorded a reserve of $18.4 million to fully reserve the investment in PMed as of December 31, 2015. FORM 990, PART VI, LINE 2 RICHARD BOALS AND WILLIAM POST HAVE A BUSINESS RELATIONSHIP. RICHARD BOALS AND ROBERT BULLA HAVE A BUSINESS RELATIONSHIP.
FORM 990, PART VI, LINE 11B	THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT AND OTHER MEMBERS OF MANAGEMENT. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS.
FORM 990, PART VI, LINE 12C	TGEN DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY KEY EMPLOYEES DESIGNATED BY THE CHIEF OPERATING OFFICER. THE QUESTIONNAIRES ARE REVIEWED BY THE CHIEF FINANCIAL OFFICER AND TGEN'S OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO THE CHIEF OPERATING OFFICER TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION.
FORM 990, PART VI, LINES 15A AND 15B	TGEN'S GOVERNANCE AND EXECUTIVE COMPENSATION COMMITTEE WILL ACT IN AN "ADVICE AND CONSENT" CAPACITY REVIEWING THE RECOMMENDATIONS FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR REGARDING THE COMPENSATION OF DISQUALIFIED PERSONS AND FORWARDING FINAL RECOMMENDATIONS TO THE FULL BOARD FOR APPROVAL. DISQUALIFIED PERSONS (EXCEPT FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR) WILL NOT BE PRESENT FOR, OR PARTICIPATE IN, COMMITTEE DELIBERATIONS CONCERNING THEIR COMPENSATION (OTHER THAN TO ANSWER QUESTIONS). THE PRESIDENT AND SCIENTIFIC DIRECTOR WILL PARTICIPATE IN THE DELIBERATIONS CONCERNING THE COMPENSATION OF DIRECT REPORTS. DURING THE DECISION MAKING PROCESS, THE COMMITTEE WILL ADHERE TO THE EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE IS AUTHORIZED (AND PROVIDED WITH SUFFICIENT FUNDING) TO ANNUALLY ENGAGE OUTSIDE INDEPENDENT COMPENSATION AND LEGAL ADVISORS, WHEN DEEMED NECESSARY AND ADVISABLE. THE COMMITTEE WILL COMPLY WITH THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE WHENEVER POSSIBLE. THE COMMITTEE WILL REVIEW AND UNDERSTAND THE INTERNAL REVENUE CODE PROVISIONS DEALING WITH "EXCESS BENEFIT TRANSACTIONS CONCERNING DISQUALIFIED PERSONS' COMPENSATION." WHEN DEVELOPING A COMPENSATION PHILOSOPHY, TGEN KEPT IN MIND THE FOLLOWING FACTORS: THE TGEN MISSION AND STRATEGY THE TGEN CULTURE TRENDS IN COMPENSATION IN THE EXTERNAL ENVIRONMENT TRENDS IN RECRUITMENT OF NEW EMPLOYEES TRENDS IN ORGANIZATIONAL EMPLOYEE TURNOVER TGEN'S LIFE CYCLE STAGE THE COMPENSATION REVIEW PROCESS WAS LAST COMPLETED IN 2015.
FORM 990, PART VI, LINE 19	THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED TO THE GENERAL PUBLIC UPON REQUEST.
FORM 990, PART VII, SECTION A, LINE 1A	TGEN HAS A BOARD OF GOVERNORS THAT IS COMPRISED OF CURRENT VOTING DIRECTORS AND SOME FORMER DIRECTORS THAT REMAIN AFFILIATED WITH TGEN IN AN ADVISORY ROLE. THE CURRENT NONVOTING ADVISORY GOVERNORS NOT LISTED AS DIRECTORS IN PART VII, SECTION A INCLUDE: BETSY BAYLESS RITA CHENG SUSAN CLARK-JOHNSON WYATT DECKER THE HONORABLE DIANE ENOS ANN WEAVER HART, PH.D. THE HONORABLE JIM SLATTERY
FORM 990, PART XI, LINE 9	BOOK TO TAX DIFFERENCE - K-1 PARTNERSHIP INCOME -396,804
FORM 990 PART XII, LINE 3B	TGEN DID UNDERGO AN AUDIT AS SET FORTH IN THE SINGLE AUDIT ACT, OMB CIRCULAR A-133 AND UNIFORM GUIDANCE AND HAD A ZERO FINDING REPORT FOR 2015.
FORM 990 PART IX LINE 11G	DESCRIPTION:CONSORTIUM/CONTRACTUAL TOTAL FEES:4110458
FORM 990 PART IX LINE 11G	DESCRIPTION:OUTSIDE RESEARCH SERVICES TOTAL FEES:1734558
FORM 990 PART IX LINE 11G	DESCRIPTION:CONSULTING TOTAL FEES:834226
FORM 990 PART IX LINE 11G	DESCRIPTION:TEMPORARY SERVICES TOTAL FEES:286811

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (5 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	EINEIN	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Total IncomeTotalIncomeAmt	End Of Year AssetsEndOfYearAssetsAmt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt
TGEN ACCELERATORS LLC (TGAM)
445 NORTH 5TH STREET SUITE 600	PHOENIX	AZ	85004	753065445	GENOMICS	AZ	$0	$0	TGEN
THE CENTER FOR TRANSLATIONAL DRUG DEV
445 N 5TH STREET SUITE 600	PHOENIX	AZ	85004	432047329	DRUG DEVEL.	AZ	-$141,435	$1,753,446	TGAM LLC
TRANSLATIONAL SYSTEMS LLC
445 N 5TH STREET SUITE 600	PHOENIX	AZ	85004	461309498	ADV. RESEARCH	AZ	$0	$0	TGEN
PET CANCER DIAGNOSTICS LLC
445 N 5TH STREET SUITE 600	PHOENIX	AZ	85004	753065445	ANIMAL DIAG.	AZ	$0	$0	TGEN
TGEN HEALTH VENTURES LLC
445 N 5TH STREET SUITE 600	PHOENIX	AZ	85004	464520712	HEALTH CARE	AZ	$1,106,596	$9,426,528	TGEN

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp

Disregarded Entity Name DisregardedEntityName

Field	Value	IRS element (for citing)
Business Name Line1	TGEN RESEARCH INSTITUTE FOUNDATION	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	445 N 5TH STREET SUITE 600	AddressLine1Txt
City	PHOENIX	CityNm
State Abbreviation	AZ	StateAbbreviationCd
ZIP	85004	ZIPCd

Field	Value	IRS element (for citing)
EIN	331092191	EIN
Primary Activities	FUNDRAISING	PrimaryActivitiesTxt
Legal Domicile State	AZ	LegalDomicileStateCd
Exempt Code Section	501(c)(3)	ExemptCodeSectionTxt
Public Charity Status	7	PublicCharityStatusTxt

Direct Controlling Entity Name DirectControllingEntityName

Field	Value	IRS element (for citing)
Business Name Line1	TGEN	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Controlled Organization	Yes (true)	ControlledOrganizationInd

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	false	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	false	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	Yes (true)	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	false	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	false	DivRelatedOrganizationInd
Asset Sale To Other Org	false	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	false	AssetPurchaseFromOtherOrgInd
Asset Exchange	false	AssetExchangeInd
Rental Of Facilities To Oth Org	false	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	false	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	false	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	Yes (true)	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	Yes (true)	SharingOfFacilitiesInd
Paid Employees Sharing	Yes (true)	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	Yes (true)	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	false	TransferToOtherOrgInd
Transfer From Other Org	false	TransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp (5 entries)

Transaction TypeTransactionTypeTxt	InvolvedInvolvedAmt	Method Of Amount DeterminationMethodOfAmountDeterminationTxt
TGEN RESEARCH INSTITUTE FOUNDATION
c	$6,881,065	ACTUAL COST
TGEN RESEARCH INSTITUTE FOUNDATION
m	$7,185,227	ACTUAL COST
TGEN RESEARCH INSTITUTE FOUNDATION
n	$108,000	ACTUAL COST
TGEN RESEARCH INSTITUTE FOUNDATION
o	$193,613	ACTUAL COST
TGEN RESEARCH INSTITUTE FOUNDATION
P	$1,172,359	ACTUAL COST